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Abstract 
Introduction: Giant Cell arteritis can be difficult to diagnose clinically. In those cases, where there is 
no certainty, there is more reliance on a temporal artery biopsy and radiological imaging to confirm 
the diagnosis. The purpose of this article was to identify the standard of care in individuals with 
suspected Giant Cell Arteritis in a typical district general hospital and to offer a proposed pathway 
for treatment. 
Methods: Darent Valley Hospital has been managing Giant Cell Arteritis for many years but there has 
always been a need for an outlined pathway to identify those at risk of cranial complications like 
visual loss to improve patient care. We evaluated the management of 70 individuals that had a 
temporal artery biopsy and followed their treatment journey. We extracted clinical specialist, 
emergency admission, operation theatre and histological data. We collected clinic follow up data 
over the following years to identify those that relapsed on treatment, stayed in remission or had 
complications.  We propose a pathway to manage those individuals with Giant Cell arteritis in line 
with the new advances in treatment. 
Results: Ten patients were identified that had a histologically positive biopsy. Reassuringly, most 
individuals with an obvious clinical diagnosis had high dose glucocorticoid treatment commenced 
before even being referred for a biopsy. Nine individuals had visual ischemia out of which five lost 
their vision. 
Conclusion: The presentation of a pathway will help streamline best medical and surgical practice 
and ensure the availability of urgent specialist treatment and to identify those at risk of ischemic 
complications.   
(Raza M, El Miedany Y. A Proposed Pathway For The Treatment of Giant Cell Arteritis: Experience 
From a District General Hospital in The United Kingdom. SEEMEDJ 2018; 2(2); 34-47) 
 
SEEMEDJ 2018, VOL 2, NO. 2 Treatment of Giant Cell Arteritis 
35 Southeastern European Medical Journal, 2018; 2(2) 
 
Introduction 
Presentation of Giant Cell Arteritis 
Temporal Arteritis (TA) is a spectrum of signs and 
symptoms involving the neck and cranial 
arteries due to a chronic inflammatory disorder. 
This can cause headaches, tender scalp, jaw 
claudication and more importantly visual loss. A 
complication of Giant Cell Arteritis (GCA), it is a 
chronic granulomatous inflammation of medium 
to large sized arteries, which can involve the 
aorta, proximal upper limb, neck, and extra 
cranial arteries. Irreversible blindness can occur 
if this arteritis involves the branches of the 
ophthalmic artery. It is called Arteritic Anterior 
Ischemic Optic Neuropathy (AAION) if it involves 
the posterior ciliary branches and and/or the 
ophthalmic artery. It is important that the patient 
have high dose glucocorticoids commenced 
immediately to prevent the progression of visual 
loss. Some individuals are at risk of losing their 
vision because of delay in commencing 
glucocorticoids (1). 
Figure 1. Clinical presentation of the patient 
with temporal arteritis (authors’ photograph) 
 
Clinical presentation 
Classically the patient will present to the clinic or 
to an emergency unit with headache and a 
tender scalp on palpation and would be unable 
to comb his/her hair. Signs will be palpation of a 
prominent, thick and tender artery with or 
without a palpable pulse. Fundoscopy might 
reveal papilledema on ophthalmological review. 
The erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP) and platelet count rise as 
an acute phase response. 
Constitutional symptoms 
Arterial lesions may be widespread and causes 
nonspecific symptoms like fever, malaise and 
night sweats. The fever can reach 38°C but fever 
of unknown origin is more common in GCA. 
Other features like malaise and weight loss may 
lead to the suspicion of malignancy leading to 
further investigations to rule out sinister causes. 
Myalgia and muscle stiffness 
The proximal muscles involving the shoulder 
and pelvic girdle are involved but distal muscles 
can also be involved. Muscle stiffness occurs 
commonly in the morning and can be 
debilitating and difficult to treat. Muscles can be 
tender causing difficulty in examining the 
strength and tone. Disuse leads to contractures 
and atrophy of muscles. The duration of 
symptoms can vary from weeks to months. 
Joint symptoms 
Patients can develop tenderness over joints 
especially over shoulder and hip joints. Synovitis 
although uncommon, can occur in the knees, 
shoulders and wrists. 
Vasculitis involving branches of the external 
carotid artery 
Headache and scalp pain are 50-75 % of the 
presenting symptoms of GCA. The headache is 
characteristically extra-cranial, boring and dull in 
nature. The occipital or posterior auricular 
branches can be involved leading to varied 
symptoms like difficulty in combing hair, pain 
behind the ear and inability to sleep using a 
pillow.  
Jaw pain and claudication has been shown to be 
a common symptom in GCA and can occur in 
almost 50% of patients (2). The involvement of 
lingual and maxillary arteries leads to pain in the 
buccinators, maxillary muscles and tongue on 
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chewing and talking. There have been reports of 
tongue gangrene although uncommon but a 
serious effect of ischaemia due to disease in the 
lingual artery. There have been cases of scalp 
necrosis secondary to GCA. This is caused by 
severe arteritis and occlusion of the branches of 
the superficial temporal artery (3). 
Vasculitis involving branches of the ophthalmic 
artery 
In patients with GCA, decreased vision 
secondary to arteritis is the most serious 
consequence. It appears that 40% of patients 
presenting with visual loss have headaches, 
constitutional symptoms and Polymyalgia 
Rheumatica (PMR). Partial visual field loss can 
progress to permanent blindness eventually. If 
unilateral visual loss is not treated, the second 
eye can be involved and can go blind in 1-2 
weeks (4).  
Involvement of the central retinal artery is about 
10%. Retinal signs and symptoms like exudates, 
haemorrhage and vasculitis are seen. Amaurosis 
fugax occurs in 10% of patients with GCA. Eighty 
percent of patients with amaurosis develop 
blindness and hence treating the patients 
urgently is of fundamental importance. 
Branches of the ophthalmic artery also supply 
the muscles to the eye and can cause diplopia 
and ptosis (5). 
Vasculitis of larger arteries 
The symptoms may be due to the involvement 
of the aortic arch and descending aorta. The 
incidence varies from 9-18%. Thoracic 
aneurysms with the presence of giant cells in the 
arterial wall can occur after a decade of the 
successful treatment of GCA. It typically 
presents in a younger age group and mostly in 
women.  
The majority of symptoms involve arm or lower 
limb claudication. Subclavian steal syndrome 
can occur due to narrowing of aortic arch roots. 
Aortic aneurysms and intestinal infarction can 
occur but renal vessel involvement is rare. GCA 
and Takayasu’s disease have overlapping signs, 
radiological findings and symptoms (6). 
Polymyalgia Rheumatica 
PMR syndrome can occur alone or in 
conjunction with Giant Cell Arteritis. Forty 
percent of patients with GCA have PMR. 
Characteristically it starts with aching in the 
shoulder and hip girdles and morning stiffness. 
Muscle weakness and elevated muscle 
enzymes unrelated to PMR. The individual 
experiences intense fatigue and malaise. There 
is a raised Erythrocyte Sedimentation Rate (ESR) 
and C-reactive protein. It is a clinical diagnosis 
and is treated with low dose GC in contrast to 
GCA where high dose GC is given. PMR can 
present with distal synovitis that can mimic 
rheumatoid arthritis. 
Patients with PMR should be warned to report 
new headaches or visual symptoms that could 
be the hallmarks of incipient GCA immediately 
(7). 
Complications secondary to GCA 
Cranial 
 
1. There can be a long interval between the 
onset of symptoms and the occurrence of 
blindness.  Temporal arteritis may not be 
apparent initially if the symptoms are subtle. 
Most commonly acute anterior ischemic optic 
neuropathy develops (8, 9, 10).  
2. Vertigo, deafness and tinnitus. 
3. The central or peripheral nervous system 
can be involved leading to strokes and transient 
ischemic attacks (9).  
4. The extent of the involvement of the 
scalp vessels depriving one area of the scalp of 
an adequate blood supply can cause scalp 
necrosis. There have been studies describing 
scalp necrosis secondary to ischaemia. In some 
case reports there have been occasions where 
debridement and skin graft was required for the 
area of skin loss (3, 11).  
Extracranial   
 
1. Intermittent claudication and rest pain of 
upper and lower extremities due to 
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inflammation in more axial large vessels can 
lead to persistent symptoms despite GC 
treatment. This requires appropriate 
investigations like magnetic resonance imaging 
and colour Doppler imaging. If symptoms 
persist, Takayasu’s aortitis needs to be ruled out 
as it can remain subclinical and quiescent 
despite being on GC therapy (12, 13).  
2. Aortitis and aortic dissection needs to be 
high in the differentials if presenting with 
atypical symptoms, backache and renal failure 
due to dissection extending down to the renal 
vessels. 
3. Cardiac murmurs like aortic regurgitation 
can lead to heart failure.  
4. Individuals can present with 
constitutional and PMR like symptoms, fever of 
unknown origin and raised inflammatory 
markers with no obvious clinical evidence of any 
aortic branch involvement. 
Incidence and epidemiology 
Over a 50-year period in Olmsted County, 
Minnesota, there were 173 incident cases of GCA 
during the 50-year study. Of these, 79% were 
women. A cyclic pattern of annual incidence 
rates was apparent, with evidence of 6 peak 
periods the mean age at diagnosis was 74.8 
years (14). There has been increasing interest in 
epidemiology of GCA where it was found to be 
more common in certain families particularly in 
the Scandinavian Countries (15). 
Investigations and Diagnosis 
Traditionally clinical suspicion from the usual 
unilateral throbbing headaches and a tender 
scalp lead to an ESR test and an immediate 
prescription of high dose oral steroids as soon as 
possible. Clinical suspicion is important with 
typical throbbing headaches, tenderness in the 
scalp and age over 50. 
TAB (temporal artery biopsy) is still performed 
quite frequently for individuals with clinical 
findings of GCA. TAB has traditionally been the 
gold standard for a diagnosis (2, 16).   
In 1990 The American College of Rheumatology 
after comparing 214 GCA individuals and 593 
patients with other forms of vasculitis, identified 
criteria to diagnose GCA. For the traditional 
format classification, five criteria are: 
1. age greater than or equal to 50 years at 
disease onset, 
2. new headache localised to the temple, 
3. temporal artery tenderness or decreased 
temporal artery pulse, 
4. elevated erythrocyte sedimentation rate 
(Westergren) greater than or equal to 50 
mm/hour,  
5. Biopsy sample including an artery 
showing necrotizing arteritis (17). 
Pathophysiology 
It is known that the inflammatory cascade 
activates early in the pathological process of 
GCA. However, the initiating event (aetiology) 
remains uncertain. There are many suspected 
pathogens. Endothelial injury leads to the cell 
mediated immunity to be stimulated leading to 
the activation of the antigen presenting cells to 
the endothelium. This triggers vascular dendritic 
cells and monocytes to produce interleukin-6 
(IL-6), IL-1 and pentraxin 3 (18). This leads to the 
stimulation of the liver to produce C- reactive 
protein (CRP). Constitutional symptoms as if 
fever and myalgia develop that are very 
responsive to glucocorticoid therapy, which 
effectively inhibits production of cells stimulated 
by Th17, which produces IL-6. 
The arterial wall is infiltrated by Th1 and Th17 
type 4p lymphocytes. Th1 lymphocytes produce 
interferon-g (IFN-g) and which result in 
formation of multinucleated giant cells from 
interaction with macrophages. Glucocorticoids 
have minimal effect on these cells showing why 
visual loss persists despite high dose applied 
(19). GC therapy can suppress mechanisms 
affected by the IL-6 like Th17 activity. The 
increasing number of circulating immune cells 
and the inability of dendritic cells to block 
access to the arterial wall via the PD-1 immune 
checkpoint suppress the natural defences. It is 
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known that the NOTCH 1 receptor on T cells and 
NOTCH-jagged 1 Ligand receptor on the vasa-
vasorum in the endothelium allow permeability 
of T cells into the vessel wall (20).  
Platelet derived growth factor (PDGF) is an 
important cytokine activating concentric intimal 
hyperplasia. PDGF comes from macrophages 
and giant cells differentiating it from other 
vasculopathies. The media of the vessel wall is 
the main site of injury. The medial macrophages 
secrete tissue destroying enzymes and 
cytokines like PDGF and vascular endothelial 
growth factor (VGEF) that also initiate repair. This 
results in a hyperplastic intima leading to 
occlusion of the vessel lumen. The intima and 
media is the centre of the pathological process. 
Cell adhesion molecules and endothelial cells 
play a pivotal role in the repair process and 
neovascularisation. Cell adhesion molecules 
might regulate how leukocytes and endothelial 
cells interact differently in different temporal 
arteries (21). Activated white cells and platelets 
cause vessel inflammation and vascular 
thrombo-embolic events, an important finding in 
diagnosing GCA.  
The inflammatory changes are quite similar to 
polymyalgia rheumatica. However, PMR is more 
of a systemic disease. The symptoms are more 
constitutional like fever malaise and weight loss. 
More specifically, there is more proximal muscle 
pain and joint pain in the shoulder, neck and 
pelvis. There is considerable chance (50%) in 
patients of TA to have PMR. 
Temporal Artery Biopsy Procedure 
The individual is consented for the biopsy and 
then brought in to the operating theatre. Ideally, 
Duplex ultrasound helps in identifying the 
temporal artery. We infiltrate local anaesthetic 
under the skin. A sterile field is created using 
drapes. A transverse or longitudinal incision is 
made on the skin just over the artery. Both ends 
of the artery are ligated with absorbable or non-
absorbable suture and a generous length is 
isolated. The artery is divided between the two 
ligatures. The skin is apposed after haemostasis 
with interrupted non-absorbable or continuous 
absorbable suture. A sterile dressing is applied 
to the wound. Non-absorbable sutures on the 
face or temple are removed in 5 days in the 
community.    
There has been a suggestion that the intra-
operative assessment can identify thickness, 
tortuosity, colour/pallor of the arterial wall, 
blood flow, and the lumen size. This gives 
enough evidence to confirm the macroscopic 
presence of TA and appropriate treatment can 
be commenced immediately. However, it 
depends on the experience of the surgeon. This 
was studied in 111 cases where the intra-
operative findings were compared with the 
histological findings and showed a 100% 
negative predictive value for biopsy negative 
specimens (22).  
Complications secondary to temporal artery 
biopsy are not common. There have been 
reports of skin necrosis after temporal artery 
biopsy due possibly to arteritis changes in 
smaller collateral arteries. Facial nerve injury can 
occur due to inadvertently not picking a safe 
zone and injuring the main branches of the facial 
nerve. Clinically this leads to weakness of 
muscles of facial expression and frontalis 
muscle weakness. Four cases of facial nerve 
injury were identified in one study. This can 
result in a permanent eyebrow droop on one 
side. It has been advocated that biopsy be 
orientated at the more parietal than frontal 
region to avoid injury to the frontal branch of the 
facial nerve (23, 24, 25). 
Histological assessment of the specimen  
The specimen is sent to the laboratory in a sterile 
pot with formalin. The dimensions of the 
specimen are measured especially the length. 
The specimen is bisected or trisected (3 mm 
each length) and then ‘embedded’. The 
specimen is dehydrated, cleared, and infiltrated 
with the embedding material. They are ready for 
external embedding. The tissue sample is 
placed into moulds along with liquid embedding 
material (such as agar, gelatine, or wax) which is 
then hardened. Longer specimens need to have 
more sections taken. Three levels each from the 
individual trisected specimen are examined 
after staining with Haematoxylin and Eosin. 
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Haematoxylin stains the nuclei blue and Eosin 
stains the cytoplasm, red blood cells and 
collagen fibres. The remaining part of specimen 
is stained with Elastic Van Giessen (EVG) staining. 
This stain is useful in demonstrating atrophy of 
elastic tissue. Specific immuno-histochemical 
stains are carried out in some institutes but the 
typical findings of giant cells and inflammatory 
cells (as below) help in earlier diagnosis (26). 
 
Figure 2. Focal granulomatous inflammation 
and sometimes giant cells are visible. Courtesy 
library.med.utah.edu 
Patients and Methods 
Study Design 
This is a retrospective case series study of 
individuals that underwent temporal artery 
biopsy in a district general hospital Darent Valley 
Hospital in Kent. There is great interest in the 
sequence of events that eventually lead to a 
TAB. Here are reviewed the events and 
outcomes of individuals that had a temporal 
artery biopsy. To achieve an adequate number 
of cases, the audit covered a number of years 
from 2009 to the current year. 
Case Retrieval 
All data of individuals undergoing a temporal 
artery biopsy were retrieved from our theatre 
link of operation records on our intranet called 
‘Theatreman’. Case notes identified by first 
identifying specific codes for ‘temporal artery 
biopsy’ from the Information Technology 
department and then were compared with 
operating theatre data and histological data. The 
case-notes were electronic through our 
Electronic Health Records (EHR). 
Biopsy results were extracted from the Darent 
Valley Hospital online Histopathology system. 
Seventy-six patients had a temporal artery 
biopsy from 2009 to 2018. All biopsies carried 
out were direct referrals form the emergency 
department and clinics. We documented all 
correspondence from the general practitioner 
and specialists. Each individual was evaluated 
using the American College of Rheumatology 
(ACR) criteria. The American College of 
Rheumatology criteria were used to diagnose 
GCA. Scoring criteria included age, headache, 
scalp tenderness, ESR and TAB results. The 
biopsy confirmed the diagnosis despite many 
individuals scoring three or four based on clinical 
suspicion and ESR. The biopsy criteria were the 
presence of inflammation and microscopic 
presence of chronic inflammatory cells in the 
muscle. There also is disruption of the internal 
elastic lamina with or without the presence of 
giant cells (27, 28).  
The history of glucocorticoids administration 
was assessed throughout the period of the 
individual’s illness. Operation notes identified the 
date of the procedure and grade of surgeon. The 
time elapsed from surgical referral to biopsy 
were recorded in days. This data was then 
transferred on to an excel sheet held on a 
computer. 
Data Collection 
A standard audit questionnaire helped in 
retrieving data. A single surgeon collected all the 
data from the case notes and later transferred all 
the data on to a Microsoft excel spreadsheet. 
The basic epidemiological data collected was 
age at biopsy, gender and mode of referral.  
Presenting symptoms were unilateral or bilateral 
headache, visual symptoms and jaw 
claudication. Signs recorded were ESR, 
ophthalmologic examination signs and scalp 
tenderness. Positive findings on scalp 
examination were tenderness by palpating the 
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artery, thickening and pulsation/no pulsation. 
We observed the duration in days from the 
surgical referral to biopsy and the date of 
commencement of corticosteroids. We 
recorded age above 50 years and ESR above 50 
mm/sec as positive criteria according to the 
ACR. The histology results documented were for 
all TABs whether positive or negative and the 
specimen length of the temporal artery. The 
grade of the operating surgeon was either a 
surgical consultant or registrar. We gave 
particular attention to the visual signs 
/symptoms like amaurosis fugax or blindness, 
the findings of fundoscopy and the 
ophthalmologist opinion.  
We documented the start date of steroid 
therapy and previous administration of steroids. 
The change in dose of steroids was not possible 
to evaluate throughout the patient’s history. 
 
 
                          Figure 3. Length of delay from diagnosis to biopsy date  
 
Results 
There were 76 individuals in the series. Only 10 
temporal artery biopsy results were positive on 
histology for temporal arteritis. Six patient’s 
notes were not retrievable. The presenting signs 






Table 1. The presenting signs and symptoms of the patients with temporal arteritis 
Age > 50 years 64/70 
ESR > 50mm  19/70 
Temporal tenderness 49/70 















SEEMEDJ 2018, VOL 2, NO. 2 Treatment of Giant Cell Arteritis 
41 Southeastern European Medical Journal, 2018; 2(2) 
 
Jaw claudication 12 
ACR scores  
                        ACR score 1 
ACR score 2 
ACR score 3 
ACR score 4 
























Biopsy findings  
                Positive biopsy  
                Negative biopsy  
10 
60 (6 inadequate 
specimens, vein,  too 
small) 
 
Description of patients  
The mean age was 67.9. The youngest age to 
have a TAB was only 38 and oldest was 87 years 
old. There were 48 women out of 70 cases (68% 
of the total).  
The mean Erythrocyte Sedimentation Rate (ESR) 
calculated was 34.9 from 66 documented 
individuals that had an ESR done. The minimum 
ESR documented was zero and maximum was 
110. There were four patients with no record of 
an ESR. 
Headaches were the most common symptoms 
as observed in our study. The pain is typically 
sudden and localised to one side of the scalp. 
However, it can occur in the parietal, occipital 
and frontal regions as well.  The headache is new 
and different from any other type of headaches. 
Twelve patients never had headaches out of the 
70 but still had a biopsy done. Nine individuals 
with headaches had bilateral involvement. 
Forty-nine of the 70 individuals had a tender 
scalp on examination as an emergency or in 
clinic review. Some cases had documentation of 
thickness or non-pulsatile artery.  
Nine individuals had pain in the muscles of 
mastication while eating and chewing 
characteristic of jaw claudication.    
The visual findings were amaurosis fugax, 
complete or partial visual loss or diplopia. Five 
patients had complete visual loss. We recorded 
visual acuity testing and finding characteristic 
signs of Acute Anterior Ischemic Occlusive Optic 
Neuritis (AAION). Four other patients had visual 
impairment with characteristic findings of AAION 
but managed to receive GC therapy urgently to 
avoid loss of vision. Six individuals had vague 
symptoms like blurring of vision and diplopia. It 
is important to note that two individuals that had 
characteristic AAION did not have histologically 
positive biopsies.  
 
Discussion 
The management of GCA begins with the clinical 
diagnosis. A biopsy is occasionally required 
when there is no clear clinical diagnosis based 
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on the ACR criteria.  The treatment revolves 
around the immediate treatment, prolonging 
remission and the prevention of relapse. The aim 
of immediate treatment is to control the 
immediate systemic inflammatory response and 
to avoid complications like acute visual loss. 
There have been extensive studies on the 
optimal treatment modalities for the last 20 
years. Glucocorticoid treatment remains the 
mainstay acute treatment for GCA despite the 
risk of adverse events.  
The immediate side effects of steroids include 
glucocorticoid effects such as hyperglycaemia 
especially in patients with diabetes mellitus and 
mineralocorticoid effects such as fluid retention. 
Other side effects include mania, psychosis and 
depression, osteoporosis, Cushing’s disease, 
obesity, new onset diabetes mellitus, peptic 
ulcers and depression on reduction or cessation 
of steroids. Less common effects are hepatic 
steatosis, avascular necrosis and weight gain. 
Prolonged administration of prednisolone may 
lead to adrenal suppression. Eventually, this may 
cause the body to temporarily lose the ability to 
manufacture natural corticosteroids especially 
cortisol, which results in dependence on 
prednisone. Prednisone is tapered if taken for 
more than seven days.  
Individuals with PMR are commonly on low dose 
prednisolone for chronic systemic symptoms. 
Clinicians should be aware of the likelihood of 
needing higher doses of steroids to combat the 
effects of GCA. Meticulous evaluation based on 
the clinical signs and symptoms is compulsory 
to avoid injudicious use of high dose steroids in 
high-risk individuals. 
 Even in this era of evolving clinical practice 
where more and more individuals are 
performing duplex ultrasonography to confirm 
or rule out a clinical diagnosis of TA, a biopsy still 
carries importance. In our trust there is growing 
enthusiasm in performing DUL in clinic on 
individuals with a suspicion of GCA (29).   
Previous studies have showed that between a 
quarter and one third of all patients having TAB 
yield a positive temporal artery biopsy. In our 
case series, the results showed that 12% of 
biopsy specimens came back positive (30). Of 
these positive biopsies, eight cases out of 10 
were an ACR score of three and above and 
probably did not need a biopsy. If we look at the 
clinical criteria, most patients had an ACR score 
of 3-4 fulfilling the diagnosis of temporal arteritis 
on the first clinical encounter and at the most 
could have benefitted with DUL without the 
need for a biopsy. We can safely treat patients 
based on clinical presentation and laboratory 
ESR findings. This will avoid unnecessary use of 
steroids on individuals with low clinical suspicion 
of GCA.  
We know that a biopsy will have a higher chance 
of being positive in the first two weeks than later. 
Twenty-five biopsies were performed within 2 
weeks in our series. Narvaez et al in his study 
evaluated the effects of duration of steroid 
treatment on biopsy results. The highest positive 
results were achieved (78%) in the individuals 
that had a biopsy within 2 weeks of commencing 
steroids. It obviously suggests that there is a 
lesser chance of getting a positive biopsy result 
in patients having a biopsy after 4 weeks of 
steroid therapy (31).  
There is considerable debate on the length of 
specimen needed to confirm GCA. GCA is a 
chronic granulomatous inflammation with skip 
lesions interspersed with normal artery sections. 
There was a general statement in all biopsy 
negative results: ‘as GCA is a patchy disease, we 
cannot exclude arteritis due to the existence of 
skip lesions in GCA.’ Skip lesions were seen in 
8.5% of specimens with active vasculitis in a 
previous study (32). The biopsy specimen is 
divided into 3-4 segments and each visualised 
under the microscope individually. Various 
studies have shown that the median specimen 
lengths for positive biopsies were ranging 
between 5mm and 12 mm but the established 
benchmark has been 1 cm and above (33). In 
another study a length of 20 mm or longer had a 
2.8 times more likelihood of having GCA 
compared to those less than 20 mm in length 
(34).  In our series, 30 specimens were at least 
1cm long prior to fixation. Forty specimens were 
shorter than 1cm or were not adequate samples. 
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There is a degree of contraction of the biopsy 
specimen before fixation with formalin. It can 
extend to 12% of contraction for GCA positive 
specimens and 22% for GCA negative 
specimens. The length of the specimen is 
calculated by measuring the in-vivo with the ex-
vivo size before fixing. If this is true then a 
specimen of 10mm would contract by more than 
2mm if negative for GCA (35).  
Complicated cranial GCA carries a high risk of 
visual loss and cerebrovascular accidents. The 
provision for ophthalmological review and 
imaging of the head needs to be readily 
available. In evolving visual changes, the 
recommendation is to administer intravenous 
GC for the first 2-3 days in hospital and then 
change to oral treatment to prevent the 
catastrophe of visual loss (26, 36).  
High dose GC treatment must continue until the 
individual’s inflammatory phase is well 
controlled. Tapering regimes of GC therapy are 
proposed in the British, European and French 
consensus guidelines (26, 37, 38).  
Numerous studies on various biological and 
non-biological agents show prolonged 
remission and reduction of recurrent relapses. 
Methotrexate has been shown to reduce the 
dose of GC required in patients with recurrent 
disease and in those which cannot take high 
dose GCs (7, 39). Recently Tocilizumab has been 
recommended in relapsing GCA in the British 
National Institute of Clinical Excellence 
guidelines (40).  
 
Table 2. Proposed pathway for the management of Temporal Arteritis  (Cont) 
 
Diagnosis: 
    Clinical        
 Age >50  
 Abrupt onset headache (usually unilateral in the temporal area)  
 Scalp pain or difficulty in combing hair  
 Visual symptoms (blurring loss/diplopia)  
 Jaw/tongue claudication  
 Systemic symptoms of fever, weight loss, loss of  
 appetite, depression and tiredness  
 Symptoms of polymyalgia rheumatica  
 Limb claudication 
 
Poor Prognostic Symptoms:        
 Features predictive of ischaemic neuro-ophthalmic complications  
 Jaw claudication  
 Visual symptoms (amaurosis fugax, and diplopia). 
          
Examination:  
 Abnormal superficial temporal artery: may be tender, thickened with reduced/absent pulsation  
 Scalp tenderness  
 Transient or permanent visual loss (partial or complete) in 20% patients  
 Visual field defect  
 Relative afferent papillary defect on swinging flashlight test  
 Anterior ischaemic optic neuritis (Pale, swollen optic disc with haemorrhages)  
 Central retinal artery occlusion  
 Upper cranial nerve palsies.  
 Features of large vessel GCA: Asymmetry of pulses and blood      pressure and bruits 
(usually of the upper limb) 
 Duplex Ultrasound(DUL)                                         
 clinic review with characteristic ‘halo’ sign 
 
SEEMEDJ 2018, VOL 2, NO. 2 Treatment of Giant Cell Arteritis 
44 Southeastern European Medical Journal, 2018; 2(2) 
 
Laboratory Investigations:  
 Markers of a raised inflammatory response  
 ESR and CRP, anaemia, thrombocytosis, raised alkaline phosphatase, raised α1 and 
α2 globulins.  
 However, Temporal arteritis can occur in the face of normal inflammatory markers, if 
the clinical picture is typical 
 
 TAB                                             
 confirmation of clinical diagnosis     
 
             MRI/FDG PET/CT                               
 suspected proximal disease                                                                                                                                                                                                                                                                                                                                                                                                                       
Differential Diagnosis:  
 Herpes zoster, migraine, cluster headache, acute angle glaucoma, TMJ pain, cervical 
spondylosis, malignancy 
 
Management of GCA: 
 Acute                                                                   
             Complicated GCA (cranial symptoms and signs)                  
 Visual ischemia           
        Hospital admission with Intravenous high dose GC 3 days                
  High dose oral GC 
 Visual loss  
      Oral 60 mg prednisolone to protect contralateral eye 
 
 Uncomplicated GCA  
          Prednisolone 60mg          
         Tapering dose of GC  
          Low dose GC +/- Methotrexate/tocilizumab for recurrent relapse or GC tapering 
Steroid Withdrawal:  
 Consider steroid reduction only in the absence of clinical symptoms, signs and lab abnormalities 
suggestive of active disease.  
 This should be balanced against the need to use the lowest effective dose, patient wishes and 
steroid side effects.  
 Suggested tapering regimen:  
40-60mgs prednisolone continued until symptoms and laboratory abnormalities resolve (at least 3 
to 4 weeks)  
Then dose reduction by 10mg every 2 weeks to 20mg,  
Then by 2.5mg every 2-4 weeks to 10 mg,  







Table 3. Proposed pathway for the management of Temporal Arteritis  (Cont) 
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After Care:  
 Rheumatology specialist review 
 Screening for cardio-vascular disease, hypertension and hyperlipidaemia  
 Bone protection and proton pump inhibition if indicated. 
 Systemic symptoms, limb claudication or persistently high-inflammatory markers despite 
adequate glucocorticosteroid therapy. PET and MRI  
 TA Patients screening for abdominal aortic aneurysms (repeat every 2 years whenever 
indicated).  
 
Monitoring of Therapy:  
 Clinical assessment + inflammatory markers  
(Evidence of relapse, disease-related complications and glucocorticosteroid-related 
complications)  
 Jaw and tongue claudication.  
 Visual symptoms.  
 Vascular claudication of limbs, bruits and asymmetrical pulses.  
 Polymyalgia symptoms.  
 Osteoporotic risk factors and fractures.  
 Perform the following investigations:  
At each visit: full blood count, ESR/CRP, urea and electrolytes, glucose.  
Every 2 years: chest radiograph to monitor for aortic aneurysm (echocardiography, PET 
and MRI may also be appropriate).  
Bone mineral density may be required. 
 
Management of Relapse:  
 Return of symptoms of GCA, ischaemic complications, unexplained fever or polymyalgia 
symptoms. 
 Return of headache  higher dose of glucocorticosteroids.  
 Jaw claudication requires 60 mg prednisolone.  
 Eye symptoms need the use of either 60 mg prednisolone or IV methylprednisolone.  
 Assessment of large vessel involvement.  
For recurrent relapse: 
 Early introduction of methortrexate or alternative immunosuppressant  
 In recurrent relapse or failure to wean glucocorticosteroid dose. These immunosuppressive 
agents should be started at the third relapse.  
 Tocilizumab has been approved for Temporal Arteritis 
 
Ophthalmological considerations                        
 Aspirin, Ophthalmology review for ischemic symptoms/signs                                                                            
 Bone protection / PPI  Omeprazole, Alendronic Acid, 




Temporal artery biopsy is useful for the 
diagnosis of cranial GCA. The various imaging 
modalities especially duplex ultrasonography 
are an important adjunct to the clinical diagnosis. 
The treatment should not be delayed if there is 
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